Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf

Molecular and Cellular Biology

Volumn 24, Issue 1, 2004, Pages 25-35

  Goueli, Basem S ^a   Janknecht, Ralf ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; RAF PROTEIN; RAS PROTEIN; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ER81; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CATALYSIS; CELL IMMORTALIZATION; CELL SURVIVAL; DNA REPLICATION; DNA STRAND BREAKAGE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBUNIT; FIBROBLAST; GENE; HTERT GENE; HUMAN; HUMAN CELL; ONCOGENE NEU; PREPUCE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION; TELOMERE; TRANSCRIPTION REGULATION;

BINDING SITES; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; RECEPTOR, ERBB-2; TELOMERASE; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 0347624599     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.1.25-35.2004     Document Type: Article

References (67)

1. Adjei, A. A. 2001. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93:1062-1074.
2. Aisner, D. L., W. E. Wright, and J. W. Shay. 2002. Telomerase regulation: not just flipping the switch. Curr. Opin. Genet. Dev. 12:80-85.
3. Baert, J. L., D. Monte, E. A. Musgrove, O. Albagli, R. L. Sutherland, and Y. de Launoit. 1997. Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int. J. Cancer 70:590-597.
4. Ben-Levy, R., H. F. Paterson, C. J. Marshall, and Y. Yarden. 1994. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 13:3302-3311.
5. Benz, C. C., R. C. O'Hagan, B. Richter, G. K. Scott, C. H. Chang, X. Xiong, K. Chew, B. M. Ljung, S. Edgerton, A. Thor, and J. A. Hassell. 1997. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15:1513-1525.
6. Blackburn, E. H. 2001. Switching and signaling at the telomere. Cell 106:661-673.
7. Block, C., R. Janknecht, C. Herrmann, N. Nassar, and A. Wittinghofer. 1996. Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo. Nat. Struct. Biol. 3:244-251.
8. Bosc, D. G., B. S. Goueli, and R. Janknecht. 2001. HER2/Neu-mediated activation of the ETS transcription factor ERS1 and its target gene MMP-1. Oncogene 20:6215-6224.
9. Bosc, D. G., and R. Janknecht. 2002. Regulation of Her2/neu promoter activity by the ETS transcription factor, ER81. J. Cell. Biochem. 86:174-183.
10. Bredemeier-Ernst, I., A. Nordheim, and R. Janknecht. 1997. Transcriptional activity and constitutive nuclear localization of the ETS protein Elf-1. FEBS Lett. 408:47-51.
11. Bruder, J. T., G. Heidecker, and U. R. Rapp. 1992. Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev. 6:545-556.
12. Cahill, M. A., R. Janknecht, and A. Nordheim. 1996. Signalling pathways: jack of all cascades. Curr. Biol. 6:16-19.
13. Chang, L., and M. Karin. 2001. Mammalian MAP kinase signalling cascades. Nature 410:37-40.
14. Cong, Y. S., J. Wen, and S. Bacchetti. 1999. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 8:137-142.
15. Davies, H., G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M. J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B. A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G. J. Riggins, D. D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J. W. Ho, S. Y. Leung, S. T. Yuen, B. L. Weber, H. F. Seigler, T. L. Darrow, H. Paterson, R. Marais, C. J. Marshall, R. Wooster, M. R. Stratton, and P. A. Futreal. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
16. Deak, M., A. D. Clifton, L. M. Lucocq, and D. R. Alessi. 1998. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 17:4426-4441.
17. De Haro, L., and R. Janknecht. 2002. Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter. Nucleic Acids Res. 30:2972-2979.
18. de Launoit, Y., J. L. Baert, A. Chotteau, D. Monte, P. A. Defossez, L. Coutte, H. Pelczar, and F. Leenders. 1997. Structure-function relationships of the PEA3 group of Ets-related transcription factors. Biochem. Mol. Med. 61:127-135.
19. Dhaene, K., J. Wauters, B. Weyn, J. P. Timmermans, and E. van Marck. 2000. Expression profile of telomerase subunits in human pleural mesothelioma. J. Pathol. 190:80-85.
20. Downward, J. 1998. Ras signalling and apoptosis. Curr. Opin. Genet. Dev. 8:49-54.
21. Drissi, R., F. Zindy, M. F. Roussel, and J. L. Cleveland. 2001. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J. Biol. Chem. 276:29994-30001.
22. Ducrest, A. L., M. Amacker, Y. D. Mathieu, A. P. Cuthbert, D. A. Trott, R. F. Newbold, M. Nabholz, and J. Lingner. 2001. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res. 61:7594-7602.
23. Ducrest, A. L., H. Szutorisz, J. Lingner, and M. Nabholz. 2002. Regulation of the human telomerase reverse transcriptase gene. Oncogene 21:541-552.
24. Favata, M. F., K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, W. S. Feeser, D. E. Van Dyk, W. J. Pitts, R. A. Earl, F. Hobbs, R. A. Copeland, R. L. Magolda, P. A. Scherle, and J. M. Trzaskos. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:18623-18632.
25. Frödin, M., and S. Gammeltoft. 1999. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell. Endocrinol. 151:65-77.
26. Graus-Porta, D., R. R. Beerli, and N. E. Hynes. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15:1182-1191.
27. Graves, B. J., and J. M. Petersen. 1998. Specificity within the ets family of transcription factors. Adv. Cancer Res. 75:1-55.
28. Hackett, J. A., D. M. Feldser, and C. W. Greider. 2001. Telomere dysfunction increases mutation rate and genomic instability. Cell 106:275-286.
29. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100:57-70.
30. Hellstrom, I., G. Goodman, J. Pullman, Y. Yang, and K. E. Hellstrom. 2001. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 61:2420-2423.
31. Hiyama, E., and K. Hiyama. 2002. Clinical utility of telomerase in cancer. Oncogene 21:643-649.
32. Hong, R. L., W. H. Spohn, and M. C. Hung. 1999. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res. 5:1884-1891.
33. Horikawa, I., P. L. Cable, C. Afshari, and J. C. Barrett. 1999. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59:826-830.
34. Horikawa, I., P. L. Cable, S. J. Mazur, E. Appella, C. A. Afshari, and J. C. Barrett. 2002. Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. Mol. Biol. Cell 13:2585-2597.
35. Hutchinson, J. N., and W. J. Muller. 2000. Transgenic mouse models of human breast cancer. Oncogene 19:6130-6137.
36. Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198:165-184.
37. Janknecht, R. 1996. Analysis of the ERK-stimulated ETS transcription factor ER81. Mol. Cell. Biol. 16:1550-1556.
38. Janknecht, R. 2001. Cell type-specific inhibition of the ETS transcription factor ER81 by mitogen-activated protein kinase-activated protein kinase 2. J. Biol. Chem. 276:41856-41861.
39. Janknecht, R. 2003. Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 22:746-755.
40. Kim, N. W., M. A. Piatyszek, K. R. Prowse, C. B. Harley, M. D. West, P. L. Ho, G. M. Coviello, W. E. Wright, S. L. Weinrich, and J. W. Shay. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015.
41. Kirkpatrick, K. L., G. Clark, M. Ghilchick, R. F. Newbold, and K. Mokbel. 2003. hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur. J. Surg. Oncol. 29:321-326.
42. Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, J. E. Strickler, M. M. McLaughlin, I. R. Siemens, S. M. Fisher, G. P. Livi, J. R. White, J. L. Adams, and P. R. Young. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746.
43. Lin, S. Y., and S. J. Elledge. 2003. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113:881-889.
44. Littlewood-Evans, A. J., G. Bilbe, W. B. Bowler, D. Farley, B. Wlodarski, T. Kokubo, T. Inaoka, J. Sloane, D. B. Evans, and J. A. Gallagher. 1997. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57:5386-5390.
45. Maida, Y., S. Kyo, T. Kanaya, Z. Wang, N. Yatabe, M. Tanaka, M. Nakamura, M. Ohmichi, N. Gotoh, S. Murakami, and M. Inoue. 2002. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 21:4071-4079.
46. McCarthy, S. A., D. Chen, B. S. Yang, J. J. Garcia Ramirez, H. Cherwinski, X. R. Chen, M. Klagsbrun, C. A. Hauser, M. C. Ostrowski, and M. McMahon. 1997. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol. Cell. Biol. 17:2401-2412.
47. McKeage, K., and C. M. Perry. 2002. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62:209-243.
48. Meltzer, P., A. Leibovitz, W. Dalton, H. Villar, T. Kute, J. Davis, R. Nagle, and J. Trent. 1991. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63:727-735.
49. Meyerson, M., C. M. Counter, E. N. Eaton, L. W. Ellisen, P. Steiner, S. D. Caddle, L. Ziaugra, R. L. Beijersbergen, M. J. Davidoff, Q. Liu, S. Bacchetti, D. A. Haber, and R. A. Weinberg. 1997. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-795.
50. Monte, D., L. Coutte, J. L. Baert, I. Angeli, D. Stehelin, and Y. de Launoit. 1995. Molecular characterization of the ets-related human transcription factor ER81. Oncogene 11:771-779.
51. Noonberg, S. B., and C. C. Benz. 2000. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59:753-767.
52. Nottage, M., and L. L. Siu. 2002. Rationale for Ras and raf-kinase as a target for cancer therapeutics. Curr. Pharm. Des. 8:2231-2242.
53. Nugent, C. I., and V. Lundblad. 1998. The telomerase reverse transcriptase: components and regulation. Genes Dev. 12:1073-1085.
54. Osherov, N., A. Gazit, C. Gilon, and A. Levitzki. 1993. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J. Biol. Chem. 268:11134-11142.
55. Pearson, K. L., T. Hunter, and R. Janknecht. 1999. Activation of Smad1-mediated transcription by p300/CBP. Biochim. Biophys. Acta 1489:354-364.
56. Poole, J. C., L. G. Andrews, and T. O. Tollefsbol. 2001. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 269:1-12.
57. Scott, G. K., C. Marden, F. Xu, L. Kirk, and C. C. Benz. 2002. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol. Cancer Ther. 1:385-392.
58. Shepherd, T. G., L. Kockeritz, M. R. Szrajber, W. J. Muller, and J. A. Hassell. 2001. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr. Biol. 11:1739-1748.
59. Takakura, M., S. Kyo, T. Kanaya, H. Hirano, J. Takeda, M. Yutsudo, and M. Inoue. 1999. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59:551-557.
60. Wosikowski, K., D. Schuurhuis, K. Johnson, K. D. Paull, T. G. Myers, J. N. Weinstein, and S. E. Bates. 1997. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J. Natl. Cancer Inst. 89:1505-1515.
61. Wu, J., and R. Janknecht. 2002. Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J. Biol. Chem. 277:42669-42679.
62. Yang, B. S., C. A. Hauser, G. Henkel, M. S. Colman, C. Van Beveren, K. J. Stacey, D. A. Hume, R. A. Maki, and M. C. Ostrowski. 1996. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol. 16:538-547.
63. Yano, Y., K. Yoshida, A. Osaki, T. Toge, H. Tahara, T. Ide, and W. Yasui. 2002. Expression and distribution of human telomerase catalytic component, hTERT, in human breast tissues. Anticancer Res. 22:4101-4107.
64. Yarden, Y. 2001. Biology of HER2 and its importance in breast cancer. Oncology 61:1-13.
65. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:127-137.
66. Yu, D., and M. C. Hung. 2000. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19:6115-6121.
67. Yu, D., B. Liu, M. Tan, J. Li, S. S. Wang, and M. C. Hung. 1996. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13:1359-1365.